EPA Science Inventory

Building an Adverse Outcome Pathway Framework through HTS Data and Literature Mining Integration (FutureToxII)

Citation:

Baker, N., N. Sipes, M. Hutson, AND T. Knudsen. Building an Adverse Outcome Pathway Framework through HTS Data and Literature Mining Integration (FutureToxII). Presented at FutureTox II, Chapel Hill, NC, January 16 - 17, 2014.

Description:

Interpreting EPA’s ToxCast in vitro assay data in the context of Adverse Outcome Pathway (AOP) development is a significant challenge. While chemical activation in these assays may shed light on the molecular initiating event, the downstream effect of these activities at higher levels of biological organization (e.g., cellular, tissue, organ) leading to a potential toxicity endpoint can be difficult to identify. In this study we have used MeSH term annotations extracted from the biomedical literature to explore the relationship between the ToxCast assays significantly associated with cleft palate/cleft lip (CP/CL) toxicants and their possible downstream cellular, tissue, and organ level phenotypes. Approximately 60 ToxCast chemicals were identified as CP/CL toxicants either through the in vivo toxicity reference database, ToxRefDB, or literature reports. There were 29 ToxCast assays significantly (p<= 0.05) associated with these chemicals from univariate analyses. These 29 assays were associated with 18 unique genes and proteins. The MeSH terms for each of these genes and proteins were used to search a literature database of over 10 million articles to find the cellular, tissue, and organ MeSH annotation terms co-occurring with the genes and proteins. The co-occurrences counts calculated for the 66,275 resulting articles produced interesting significant connections. The ToxCast target leukocyte elastase, for instance, is highly co-annotated with the terms Cell Adhesion, Extracellular Matrix, and Connective Tissue, suggesting it should be examined for a possible role in extracellular matrix regulation during palate development. While cleft palate is used as an example, this robust literature mining technique has the potential to provide insight into AOP development for a broad range of toxicity endpoints. This abstract does not necessarily reflect US EPA policy.

Purpose/Objective:

Interpreting EPA’s ToxCast in vitro assay data in the context of Adverse Outcome Pathway (AOP) development is a significant challenge. While chemical activation in these assays may shed light on the molecular initiating event, the downstream effect of these activities at higher levels of biological organization (e.g., cellular, tissue, organ) leading to a potential toxicity endpoint can be difficult to identify.

URLs/Downloads:

NANCY_BAKER_FUTURETOXII_POSTER_FINAL.PDF   (PDF,NA pp, 748.597 KB,  about PDF)

BAKER_FUTURETOX2014 ABSTRACT.PDF   (PDF,NA pp, 75.915 KB,  about PDF)

Record Details:

Record Type: DOCUMENT (PRESENTATION/POSTER)
Start Date: 01/17/2014
Completion Date: 01/17/2014
Record Last Revised: 08/25/2014
Record Created: 08/25/2014
Record Released: 08/25/2014
OMB Category: Other
Record ID: 284684

Organization:

U.S. ENVIRONMENTAL PROTECTION AGENCY

OFFICE OF RESEARCH AND DEVELOPMENT

NATIONAL CENTER FOR COMPUTATIONAL TOXICOLOGY